Increased Bargaining Power of Medical Institutions and Distributors
First written in FY2016. 12 of 14 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2025: 3 of 7 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of stronger pricing power among medical institutions and distributors. - FY2018-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes to the risks in the previous fiscal year. - FY2017DroppedAnnual report
「The following are the principal risks that could affect the operating results and financial condition of the group.」
The stronger pricing power of medical institutions and distributors, which was described in FY2016, was not listed separately among the 4 principal risks in FY2017. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The risk of stronger pricing power among medical institutions and distributors is treated as having undergone no material changes. - FY2017-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk of stronger pricing power among medical institutions and distributors is treated as having undergone no material changes. - FY2017-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes to the risks described in the previous year's securities report. - FY2016First statedAnnual report
「Customers' pricing power over the company has also strengthened as medical institutions participate in group purchasing and distributors have grown larger.」
The company describes stronger pricing power driven by group purchasing by medical institutions and the consolidation and expansion of distributors.